Showing papers in "American Journal of Transplantation in 2004"

TL;DR: This work analyzed data provided by the Scientific Registry of Transplant Recipients regarding all adult first renal transplants between 1995 and 2000 to investigate how acute rejection rates have evolved on a national level in the U.S and how this has impacted graft survival in the most recent era of kidney transplantation.

TL;DR: The continuing risk for lymphoma with time post‐transplantation, the contribution of immunosuppression to increased risk, and continuing poor outcomes in patients with post-transplant lymphoma are highlighted.

TL;DR: A large number of patients in single‐center studies and incomplete ascertainment of cases in large registries suggest that cancer after kidney transplantation is a major cause of death in these patients.

TL;DR: Once‐daily oral valganciclovir was as clinically effective and well‐tolerated as oral ganciclovIR tid for CMV prevention in high‐risk SOT recipients and the safety profile was similar for both drugs.

TL;DR: This work aimed, now with sufficient follow up available, to calculate real half‐lives of renal allograft survival improvement between 1988 and 1995 using projections of half-lives based on limited actual follow up.

TL;DR: TGF‐β is a key regulator of the signaling pathways that initiate and maintain Foxp3 expression and suppressive function in CD4 + CD25 − precursors and may be key components for the manipulation of Treg.

TL;DR: A meta‐analysis evaluates the reported incidence of NODM after solid organ transplantation in patients receiving CNI treatment and concludes that new onset diabetes mellitus is a serious complication of transplantation.

TL;DR: The novel immunomodulator FTY720 acts as a high‐affinity agonist at the G protein‐coupled sphingosine 1‐phosphate receptor‐1 on thymocytes and lymphocytes, thereby inducing aberrant internalization of the receptor.

TL;DR: The process of humoral rejection is multifaceted and has different manifestations in the various types of organ transplants.

TL;DR: Patients with HLA antibodies had graft failure at a significantly higher rate than those without antibodies after 1 year in this prospective trial.

TL;DR: Preliminary results suggest that a combination of maximized viable islet yield, pretransplant islet culture, and preemptive immunosuppression can result in successful single‐donor islet transplants.

TL;DR: Biopsies showing lesser degrees of renal scarring at the time of diagnosis were associated with, more likely, resolution of the infection, in response to decrease of immunosuppression, and correlated with worse graft outcome.

TL;DR: It is shown that a high density of CD 20+ cells are seen in patients who have steroid‐resistant rejection episodes, and Rituximab is a rational choice for therapy in transplantation to abrogate B‐cell‐mediated events.

TL;DR: Long‐term outcome in recipients of ABO‐incompatible living kidneys is excellent, and graft survival rates were significantly higher in patients 29 years or younger than in patients 30 years or older and in patients who received anticoagulation therapy than in those who did not receive such therapy.

TL;DR: A major challenge for kidney transplantation is balancing the need for immunosuppression to prevent rejection, while minimizing drug‐induced toxicities.

TL;DR: These guidelines, which are a modified version of the K/DOQI dyslipidemia guidelines, were developed to aid clinicians in the management of dyslipidemias in kidney transplant patients and are supported mainly by data from studies in the general population but there is an urgent need for additional studies in CKD and in transplant patients.

TL;DR: The data presented in this paper suggest that the development or progression of these lesions could be ameliorated by restoring renal function with a transplant and the CVD rates on the transplant waiting list increased sharply and progressively by wait listing vintage.

TL;DR: At 2 years the sirolimus‐treated recipients have better renal function, a diminished prevalence of CAN and down‐regulated expression of genes responsible for progression of CAN, which may provide for an alternative natural history with improved graft survival.

TL;DR: Therapeutic equivalence of EC‐MPS and MMF (1000 mg MMF b.i.d.), with concomitant cyclosporine microemulsion (Neoral®) and corticosteroids, was assessed in 423 de novo kidney transplant patients recruited to a 12‐month, double‐blind study.

TL;DR: The association of induction therapy by immunosuppression with antilymphocyte antibodies, with the development of de novo neoplasms among kidney recipients is studied.

TL;DR: In this retrospective observational cohort study, patients with multiple listings at different transplant centers and patients who changed transplant centers were counted only once and the Social Security Death Master File and the UNOS kidney transplant database were used to update mortality information.

TL;DR: The use of rituximab, allowing avoidance of splenectomy, may further remove one of the significant disincentives to ABOi transplantation, and eliminate the risk of post‐splenectomy infections.

TL;DR: Systemically phenotyped peripheral blood mononuclear cells from operationally tolerant patients to provide important clues for reliable indicators of tolerance after LDLT and the contribution of those subsets to the tolerant state remains elusive.

TL;DR: In conclusion, renal maintenance patients can be converted from MMF to EC‐MPS without compromising the safety and efficacy profile associated with MMF.

TL;DR: Several aspects of the new allocation, including the development and evolution of MELD and PELD, the relationship between the two scoring systems, and the resulting effect on access to transplantation and waiting list mortality are examined.

TL;DR: An initial dosing regimen for tacrolimus based on knowledge of the CYP3AP1 genotype and subsequently guided by concentration measurements has the potential to increase the proportion of patients achieving target blood concentrations early after transplantation.

TL;DR: Concentration‐controlled everolimus with low‐exposure CsA provided effective protection against rejection with good renal function in de novo renal transplant patients.

TL;DR: Proteinuria at conversion below 800 mg/day is the only independent predictor for positive outcome in conversion from CNI to SRL in CAD, and in a multivariate analysis low proteinuria was theOnly independent variable.

TL;DR: The Seventh Banff Conference on Allograft Pathology was held June 14–18, 2003 in Aberdeen, Scotland representing the latest iteration of the international consensus meeting, which develops worldwide standards for interpretation of allograft biopsies.

TL;DR: The ability of CP‐690550 to extend cardiac allograft survival in murine models suggests it may afford a new treatment for prevention of transplant rejection and support the participation of JAK‐3 in various lymphocyte homeostatic functions in mature mice.